1. Stanley Nattl,Bramdh N,Singh. Evolution Mechanisms, and classif cation of Antiarrhythmis Prugs: Focus on Class Ⅲ Actions, Vol.84(9A),The American Journal of Cardiology.1999 2. PeterR.kowey,RogerA.Marinchak,SethJ,Rial,David Bharueha. Pharmacologic and Pharmaco Kinetic Prof le of Class . Ⅲ Antiarrhythmic Brugs. Vol.80(8A),The American Journal of Caroliology,1997. 3. Shunichi Kushida, Takehiko Vgura, Issei Konuro, Haruaki Nakya, Ihibitory effete of the class Ⅲ antiarht thmac drug nilekalant on HERG channel:mode of action .European Journal of pharmacology 457(2002) 19-27, 4. Bramdh N,Singh. The coming age of the class Ⅲ antiarrhythmic principle:retrospective and future trends. Vol.78(4A).The American Journal of Caroliology. 1996 5. 冉崇昭,谢美华,Ⅲ型抗心律失常药物研究进展,中国医药工业杂志,2001 32(10) 6. 刘文波,任法鑫,心律失常的基因治疗,医学综述,2003(11) 7. 李延昌,万秀芝,搞心律失常药物的临床评价及研究进展V01.24,2002(8) 8. 胡大一,刘兴鹏 心律失常药物治疗的若干进展,中国介入心脏病学杂志, VO1.11 2003. 9. 秦玲,郑杨,高沿航,索他洛尔治疗室性早博,吉林大学学报, V01.28 2002。 10. 赵京林,樊朝美,多非利特:一种新型纯Ⅲ类抗心律失常药物,中国临床药理学杂志V018.2002. 11. 陈椿,抗心律失常药物索他洛尔临床研究进展,中国心脏起博与心电生理杂志. V0l(14)2000. |